Avadel Pharmaceuticals plc Stock News

We are initiating AVDL at a speculative buy rating, with a target price of USD 14.

Avadel Pharmaceuticals plc's (AVDL) CEO Gregory Divis on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

Avadel Pharmaceuticals (NASDAQ: AVDL ) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Avadel Pharmaceuticals beat estimated earnings by 7.32%, reporting … Full story available on Benzinga.com

Avadel Pharmaceuticals press release (AVDL): Q4 GAAP EPS of -$0.38 beats by $0.03.Cash, cash equivalents and marketable securities were $157.2 million as of December 31, 2021.

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ: TGA ) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ: IKNA ) is projected to report earnings for its fourth quarter. • RF Industries (NASDAQ: RFIL ) is likely to report quarterly earnings at $0.04 per share on revenue of $15.84 million. • Destination XL Group (NASDAQ: DXLG ) is estimated to report quarterly earnings at $0.13 per share on revenue of $131.88 million. • Liquidia (NASDAQ: LQDA ) is projected to report quarterly loss at $0.11 per share on revenue of $3.05 million. • IMV (NASDAQ: IMV ) is projected to report quarterly loss at $0.13 per share on revenue of $50.00 thousand. • Redhill Biopharma (NASDAQ: RDHL ) is likely to report quarterly loss at $0.33 per share on revenue of $24.08 million. • Designer Brands (NYSE: DBI ) is likely to report quarterly earnings at $0.16 per share on revenue of $839.61 million. • Kirkland''s (NASDAQ: KIRK ) is expected to report quarterly earnings at $0.

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Bran

On Friday, the clinical-stage pharma company, Avadel Pharmaceuticals (AVDL) announced additional data for the company’s lead asset FT218 from a pivotal late-stage trial and an…

DUBLIN, Ireland, March 11, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data will be presen

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at the Oppenheimer 32 nd Annual Healthcare Conference on Thursday, March 17 at 10:40 a.m. ET.

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Ex

Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s traded shares stood at 0.36 million during the last session, with the company’s beta value hitting 1.02. At the close of trading, the stock’s price was $7.49, to imply a decrease of -1.71% or -$0.13 in intraday trading. The AVDL share’s 52-week high remains $11.59, putting it -54.74% down since that … Avadel Pharmaceuticals plc (NASDAQ: AVDL) Has Succeeded To Excite In 2022, The Stock Is Down -7.30% Year-To-Date Read More »

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Dougl

DUBLIN, Ireland , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson , MBChB, as Chief Medical Officer. “Doug is an outstanding addition to the Avadel